A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non–small cell lung cancer with <i>EGFR</i> mutation-Reference-Cited by-同舟云学术

A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non–small cell lung cancer with EGFR mutation

Published:2022-11-30 Issue:3 Volume:129 Page:405-414
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Lee Youngjoo¹^ORCID,Kim Hye Ryun²,Hong Min Hee²^ORCID,Lee Ki Hyeong³,Park Keon Uk⁴^ORCID,Lee Geon Kook⁵,Kim Hyae Young⁶,Lee Soo‐Hyun⁶,Lim Kun Young⁶,Yoon Sung Jin¹,Cho Byoung Chul²,Han Ji‐Youn¹

Affiliation:

1. Center for Lung Cancer National Cancer Center Goyang Republic of Korea

2. Division of Medical Oncology Department of Internal Medicine Yonsei Cancer Center Yonsei University College of Medicine Seoul Republic of Korea

3. Department of Internal Medicine Chungbuk National University Hospital Cheongju Republic of Korea

4. Department of Internal Medicine Keimyung University Dongsan Hospital Daegu Republic of Korea

5. Department of Pathology National Cancer Center Goyang Republic of Korea

6. Department of Radiology National Cancer Center Goyang Republic of Korea

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.34553

Reference27 articles.

1. Targeted therapy for non‐small cell lung cancer: current standards and the promise of the future;Chan BA;Transl Lung Cancer Res,2015

2. Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

3. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

4. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Aryl Hydrocarbon Receptor Controls IFNγ-Induced Immune Checkpoints PD-L1 and IDO via the JAK/STAT Pathway in Lung Adenocarcinoma;2024-08-13

2. The incidence of drug-induced interstitial lung disease caused by epidermal growth factor receptor tyrosine kinase inhibitors or immune checkpoint inhibitors in patients with non-small cell lung cancer in presence and absence of vascular endothelial growth factor inhibitors: a systematic review;Frontiers in Oncology;2024-06-11

3. Progress of Angiogenesis Signal Pathway and Antiangiogenic Drugs in Nasopharyngeal Carcinoma;Current Molecular Pharmacology;2024-05-17

4. The role of angiogenesis inhibitors associated with tyrosine kinase inhibitors in the first-line treatment for EGFR-mutated advanced lung cancer;Critical Reviews in Oncology/Hematology;2024-04

5. Investigating the Efficacy of EGFR-TKIs and Anti-VEGFR Combination in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis;Cancers;2024-03-18